STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies* 

	Item No	Recommendation	Page No
Title and abstract	١	(a) Indicate the study's design with a commonly used term in the title or	
		the abstract	
		(b) Provide in the abstract an informative and balanced summary of what	
		was done and what was found	
Introduction			•
Background/rationale	۲	Explain the scientific background and rationale for the investigation being	
		reported	
Objectives	٣	State specific objectives, including any prespecified hypotheses	
Methods			
Study design	٤	Present key elements of study design early in the paper	
Setting	٥	Describe the setting, locations, and relevant dates, including periods of	
		recruitment, exposure, follow-up, and data collection	
Participants	٦	(a) Give the eligibility criteria, and the sources and methods of selection of	
		participants	
Variables	٧	Clearly define all outcomes, exposures, predictors, potential confounders,	
		and effect modifiers. Give diagnostic criteria, if applicable	
Data sources/	۸*	For each variable of interest, give sources of data and details of methods	
	~	of assessment (measurement). Describe comparability of assessment	
measurement			
D'	٩	methods if there is more than one group	
Bias		Describe any efforts to address potential sources of bias	
Study size	1.	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	
		applicable, describe which groupings were chosen and why	
Statistical methods	17	(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) If applicable, describe analytical methods taking account of sampling	
		strategy	
		(e) Describe any sensitivity analyses	
Dogulta		(E) Describe any sensitivity analyses	1
Results Participants	17*	(a) Report numbers of individuals at each stage of study—eg numbers	
Tarticipants		potentially eligible, examined for eligibility, confirmed eligible, included	
		in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
Descriptive data	<b>A</b> / J.	(c) Consider use of a flow diagram	
	۱٤*	(a) Give characteristics of study participants (eg demographic, clinical,	
		social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of	
		interest	
Outcome data	10*	Report numbers of outcome events or summary measures	
Main results	١٦	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	
		estimates and their precision (eg, ٩٥% confidence interval). Make clear	
		which confounders were adjusted for and why they were included	

		(b) Report category boundaries when continuous variables were	
		categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute	
		risk for a meaningful time period	
Other analyses	١٧	Report other analyses done—eg analyses of subgroups and interactions,	
		and sensitivity analyses	
Discussion			
Key results	١٨	Summarise key results with reference to study objectives	
Limitations	۱۹	Discuss limitations of the study, taking into account sources of potential	
		bias or imprecision. Discuss both direction and magnitude of any potential	
		bias	
Interpretation	۲.	Give a cautious overall interpretation of results considering objectives,	
		limitations, multiplicity of analyses, results from similar studies, and other	
		relevant evidence	
Generalisability	71	Discuss the generalisability (external validity) of the study results	
Other information			
Funding	77	Give the source of funding and the role of the funders for the present study	-
		and, if applicable, for the original study on which the present article is	
		based	

<sup>\*</sup>Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.